A detailed history of Los Angeles Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 420,748 shares of NBIX stock, worth $56.8 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
420,748
Previous 56,885 639.65%
Holding current value
$56.8 Million
Previous $7.83 Million 518.57%
% of portfolio
0.2%
Previous 0.03%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$114.58 - $153.15 $41.7 Million - $55.7 Million
363,863 Added 639.65%
420,748 $48.4 Million
Q2 2024

Aug 05, 2024

SELL
$130.86 - $143.19 $24.7 Million - $27 Million
-188,496 Reduced 76.82%
56,885 $7.83 Million
Q1 2024

Apr 05, 2024

SELL
$130.4 - $143.74 $87.8 Million - $96.7 Million
-673,010 Reduced 73.28%
245,381 $33.8 Million
Q4 2023

Feb 06, 2024

BUY
$106.07 - $132.76 $38.7 Million - $48.5 Million
364,986 Added 65.95%
918,391 $121 Million
Q3 2023

Nov 06, 2023

BUY
$94.02 - $117.1 $263,914 - $328,699
2,807 Added 0.51%
553,405 $62.3 Million
Q2 2023

Aug 03, 2023

SELL
$89.53 - $104.87 $7.54 Million - $8.83 Million
-84,247 Reduced 13.27%
550,598 $51.9 Million
Q1 2023

May 04, 2023

SELL
$94.11 - $123.02 $12.1 Million - $15.9 Million
-128,847 Reduced 16.87%
634,845 $64.3 Million
Q4 2022

Feb 06, 2023

SELL
$106.72 - $127.06 $3.02 Million - $3.59 Million
-28,274 Reduced 3.57%
763,692 $91.2 Million
Q3 2022

Nov 02, 2022

BUY
$92.03 - $107.81 $72.9 Million - $85.4 Million
791,966 New
791,966 $84.1 Million
Q4 2021

Feb 03, 2022

SELL
$79.65 - $106.22 $1.12 Million - $1.49 Million
-14,016 Closed
0 $0
Q3 2021

Nov 08, 2021

SELL
$86.18 - $99.03 $446,153 - $512,678
-5,177 Reduced 26.97%
14,016 $1.34 Million
Q2 2021

Aug 05, 2021

SELL
$89.43 - $102.27 $3.24 Million - $3.71 Million
-36,255 Reduced 65.39%
19,193 $1.87 Million
Q1 2021

May 05, 2021

SELL
$87.57 - $119.4 $7.9 Million - $10.8 Million
-90,189 Reduced 61.93%
55,448 $5.39 Million
Q4 2020

Feb 04, 2021

SELL
$86.91 - $108.33 $2.7 Million - $3.37 Million
-31,120 Reduced 17.61%
145,637 $14 Million
Q3 2020

Nov 02, 2020

BUY
$96.16 - $135.15 $4.2 Million - $5.9 Million
43,631 Added 32.77%
176,757 $17 Million
Q2 2020

Aug 05, 2020

BUY
$85.09 - $130.36 $10.4 Million - $16 Million
122,431 Added 1144.75%
133,126 $16.2 Million
Q1 2020

May 04, 2020

BUY
$75.11 - $113.76 $179,888 - $272,455
2,395 Added 28.86%
10,695 $926,000
Q4 2019

Feb 07, 2020

BUY
$86.8 - $118.57 $410,564 - $560,836
4,730 Added 132.49%
8,300 $892,000
Q3 2019

Nov 07, 2019

SELL
$83.82 - $101.5 $1.21 Million - $1.46 Million
-14,380 Reduced 80.11%
3,570 $322,000
Q2 2019

Jul 29, 2019

SELL
$72.24 - $91.27 $510,014 - $644,366
-7,060 Reduced 28.23%
17,950 $1.52 Million
Q1 2019

Apr 25, 2019

BUY
$69.31 - $91.53 $1.46 Million - $1.93 Million
21,040 Added 529.97%
25,010 $2.2 Million
Q4 2018

Feb 11, 2019

BUY
$68.32 - $124.36 $128,441 - $233,796
1,880 Added 89.95%
3,970 $283,000
Q3 2018

Nov 05, 2018

SELL
$98.88 - $125.85 $353,001 - $449,284
-3,570 Reduced 63.07%
2,090 $257,000
Q2 2018

Jul 31, 2018

SELL
$75.3 - $105.99 $181,473 - $255,435
-2,410 Reduced 29.86%
5,660 $556,000
Q1 2018

Apr 27, 2018

BUY
$75.88 - $92.43 $612,351 - $745,910
8,070 New
8,070 $669,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.